# Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Source: https://onco.cc/trials/nct02628067/  
OnCo record `nct02628067` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pembrolizumab in metastatic cancer and biliary tract cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) is a phase 2 interventional study registered as NCT02628067 by Merck Sharp & Dohme LLC, with 1609 participants planned, started 2015-12-18 and due to reach its primary completion in 2027-05-04. Interventions recorded: pembrolizumab, pembrolizumab. Conditions listed: Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02628067
- Phase: 2
- Setting: A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 1609

## Sources

- ClinicalTrials.gov NCT02628067: https://clinicaltrials.gov/study/NCT02628067

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Vulvar cancer](https://onco.cc/cancers/vulvar/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct02628067.json